重组人脑利钠肽、沙库巴曲缬沙坦、托伐普坦序贯治疗高龄射血分数降低的心力衰竭病人的疗效观察

doi:10.3969/j.issn.1003-9198.2021.09.016

摘要/Abstract

摘要： 目的观察重组人脑利钠肽、沙库巴曲缬沙坦、托伐普坦序贯治疗高龄射血分数降低的心力衰竭(HFrEF)病人的疗效。方法选择我科80~90岁HFrEF病人40例,随机分为常规治疗组和序贯治疗组,每组20例。常规治疗组予以常规抗心衰药物治疗;序贯治疗组在停用血管紧张素转化酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)基础上序贯使用重组人脑利钠肽、沙库巴曲缬沙坦、托伐普坦。治疗前后分别采用明尼苏达心衰生活质量问卷表(MLHFQ)、6 min步行试验(6MWT)评估病人心功能情况,采用心脏彩色多普勒超声检测病人LVEF、心排血量(CO)、每搏输出量(SV),同时检测病人血浆BNP、肾功能及血清电解质水平。结果治疗10 d后,序贯治疗组总有效率显著高于常规治疗组(P＜0.05);2组MLHFQ评分、6 min步行距离、LVEF、CO、SV、血浆BNP水平均较治疗前改善,且序贯治疗组上述指标较常规治疗组改善更明显(均P＜0.05);常规治疗组血清K⁺、Na⁺水平均较治疗前下降(P＜0.05),但序贯治疗组血清电解质水平较治疗前无明显变化(P＞0.05)。2组病人肾功能指标治疗前后无明显变化(P＜0.05)。结论重组人脑利钠肽、沙库巴曲缬沙坦、托伐普坦序贯治疗可以优势互补,有效改善高龄HFrEF病人的心功能状况。

关键词: 重组人脑利钠肽, 沙库巴曲缬沙坦, 托伐普坦, 老年人, 心力衰竭

Abstract: Objective To investigate the curative effect of sequential treatment of recombinant human brain natriuretic peptide, sacubitril/valsartan and tolvaptan on the elderly patients with heart failure with reduced ejection fraction (HFrEF). Methods A total of 40 patients with HFrEF aged 80 to 90 years old were randomly divided into conventional treatment group and sequential treatment group,with 20 cases in each group. The patients in conventional treatment group were treated with conventional anti-heart failure drugs. The patients in sequential treatment group were sequentially treated with recombinant human brain natriuretic peptide, sacubitril/valsartan and tolvaptan on the basis of stopping angiotensin converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blocker (ARB). Minnesota Living with Heart Failure Questionnaire (MLHFQ) and 6-minute walking test (6MWT) were used to evaluate the cardiac function of the patients, and cardiac color Doppler ultrasound was used to detect the left ventricular ejection fraction (LVEF), cardiac output (CO) and stroke volume (SV) of the patients. Additionally, the levels of plasma brain natriuretic peptide (BNP), renal function and serum electrolytes were also detected. Results After 10 days of treatment, the total effective rate of sequential treatment group was significantly higher than that of conventional treatment group (P＜0.05);The MLHFQ score, 6MWT distance, and the levels of LVEF, CO, SV and plasma BNP in both groups were all improved (P＜0.05), especially in sequential treatment group (P<0.05); The serum levels of K⁺ and Na⁺ in conventional treatment group were significantly lower than those before treatment (all P＜0.05), whereas there were no significant differences in the serum electrolytes levels of sequential treatment group after treatment (all P＞0.05). In addition, there was no significant change in renal function of both groups after treatment (all P＞0.05). Conclusions The sequential treatment of recombinant human brain natriuretic peptide, sacubitril/valsartan and tolvaptan could improve the cardiac function of the elderly patients with HFrEF effectively.

Key words: recombinant human brain natriuretic peptide, sacubitril/valsartan, tolvaptan, aged, heart failure

中图分类号:

R 541.6

权乾坤, 冯建军, 李玺, 李婉妮, 张秀丽, 刘春田. 重组人脑利钠肽、沙库巴曲缬沙坦、托伐普坦序贯治疗高龄射血分数降低的心力衰竭病人的疗效观察[J]. 实用老年医学, 2021, 35(9): 957-961.

QUAN Qian-kun, FENG Jian-jun, LI Xi, LI Wan-ni, ZHANG Xiu-li, LIU Chun-tian. Effect of sequential treatment of recombinant human brain natriuretic peptide, sacubitril/valsartan and tolvaptan on elderly patients with heart failure with reduced ejection fraction[J]. Practical Geriatrics, 2021, 35(9): 957-961.

参考文献

[1] 王宙, 周琳, 刘洋, 等. 慢性心力衰竭的流行病学研究现状及其防治研究进展[J]. 中国循证心血管医学杂志, 2019, 11(8):1022-1024.
[2] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9):833-854.
[3] 顾东风, 黄广勇, 何江, 等. 中国心力衰竭流行病学调查及其患病率[J]. 中华心血管病杂志, 2003, 31(1):3-6.
[4] MCMURRAY J J V, PACKER M, DESAI A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004.
[5] YANCY C W, JESSUP M, BOZKURT B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [J]. Circulation, 2017, 136(6):e137-e161.
[6] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[7] 成蓓, 曾尔亢. 老年病学[M]. 北京: 科学出版社, 2018:83-85.
[8] 国家卫生计生委合理用药专家委员会,中国药师协会. 心力衰竭合理用药指南(第2版)[J]. 中国医学前沿杂志:电子版, 2019, 11(7):1-78.
[9] 杨昌林. 沙库巴曲缬沙坦钠片治疗高龄慢性心力衰竭效果观察[J]. 人民军医, 2019, 62(9):847-849, 855.
[10] 李世泽, 史哲. 益心舒胶囊治疗180例慢性收缩性心力衰竭患者的疗效观察[J]. 中国医院用药评价与分析, 2012, 12(1):58-59.
[11] FU S H, PING P, WANG F Q, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure[J]. J Biol Eng, 2018, 12. DOI: 10.1186/s13036-017-0093-0.
[12] 重组人脑利钠肽临床研究协作组. 重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J]. 中华心血管病杂志, 2006, 34(3):222-226.
[13] 胡熙苒, 齐亮, 陈翀. 连续负荷剂量重组人脑利钠肽治疗慢性心力衰竭[J]. 实用医药杂志, 2019, 36(2):138-140.
[14] NOUGUÉ H, PEZEL T, PICARD F, et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study[J]. Eur J Heart Fail, 2019, 21(5):598-605.
[15] RODGERS J E. Sacubitril/valsartan: the newest addition to the toolbox for guideline-directed medical therapy of heart failure[J]. Am J Med, 2017, 130(6):635-639.
[16] 李迪, 何元军, 潘雪琴. 重组人脑利钠肽治疗心律失常疗效及安全性的量效作用观察[J]. 中西医结合心脑血管病杂志, 2018, 16(15):2169-2173.
[17] 程小航, 张宸, 刘善伟, 等. 托伐普坦在心力衰竭治疗的研究进展[J]. 中国循证心血管医学杂志, 2018, 10(11):1436-1438.
[18] 李莉莉. 托伐普坦治疗难治性心力衰竭的有效性及安全性[J]. 中国保健营养, 2019, 29(36):250.
[19] OKABE T, YAKUSHIJI T, IGAWA W, et al. The efficacy of tolvaptan in congestive heart failure patients with and without hypoalbuminemia: a pilot study[J]. Cardiovasc Ther, 2015, 33(5):275-281.
[20] 孟令光. 冻干重组人脑利钠肽急诊治疗急性心力衰竭患者的效果[J]. 中华灾害救援医学, 2020, 8(5):244-247.
[21] 葛慧娟. 重组人脑利钠肽对于急性心肌梗死后老年心力衰竭患者疗效及预后的影响[J]. 中国老年学杂志, 2016, 36(3):602-604.
[22] 蔡香香. 重组人脑利钠肽对老年慢性心衰急性加重期患者心功能及BNP水平的影响[J]. 当代医学, 2021, 27(2):139-140.